Lipella Pharmaceuticals, Inc. Additionally, Lipella focuses on enhancing the surveillance and imaging capabilities for patients with a history of transitional cell carcinoma. They have made significant advancements in drug delivery to the oral mucosa for the treatment of oral lichen planus.

Lipella Pharmaceuticals recently completed a groundbreaking phase 2A clinical trial for their flagship product, LP-10, with promising results on the horizon. They also have a robust pipeline of additional product candidates, developed with the aim of addressing highly-morbid indications that lack adequate treatment options. Committed to excellence, Lipella Pharmaceuticals maintains a state-of-the-art sterile manufacturing facility in Pittsburgh, PA, dedicated to producing clinical supplies and research products.

Their dedication to innovation and patient care has earned them recognition in the industry. For those interested in investment opportunities, Lipella will be presenting at Biotech Showcase 2023 on January 11, 2023, showcasing their latest developments. With a strong commitment to ethics and transparency, Lipella Pharmaceuticals is poised to make a significant impact on the field of biotechnology